KPC Pharmaceuticals Inc
SSE:600422
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
KPC Pharmaceuticals Inc
Accounts Payable
KPC Pharmaceuticals Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
KPC Pharmaceuticals Inc
SSE:600422
|
Accounts Payable
¥876.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Payable
¥334.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Payable
¥2.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Payable
¥7.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Accounts Payable
¥1.9B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accounts Payable
¥498m
|
CAGR 3-Years
90%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
KPC Pharmaceuticals Inc
Glance View
KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.
See Also
What is KPC Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
876.2m
CNY
Based on the financial report for Dec 31, 2025, KPC Pharmaceuticals Inc's Accounts Payable amounts to 876.2m CNY.
What is KPC Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
11%
Over the last year, the Accounts Payable growth was -17%. The average annual Accounts Payable growth rates for KPC Pharmaceuticals Inc have been 8% over the past three years , 6% over the past five years , and 11% over the past ten years .